Don Gabriel joins United BioSource Corp.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DON GABRIEL joined the Global Clinical Development & Operations team of United BioSource Corp., a subsidiary of Express Scripts. Gabriel will direct UBC’s consultative services to pharmaceutical sponsors developing oncology therapies.

A bone marrow transplant physician, Gabriel held a long tenure at the University of North Carolina where he served as professor of medicine, associate chief of staff, assistant dean for clinical services, acting chief of medical oncology, and service chief liaison of the Division of Hematology/Oncology.

He has co-developed an optical laser-based technology used to identify and characterize suspended particles in the blood, including circulating tumor cells.

“Joining UBC gives me the opportunity to work with an organization that is using cutting edge clinical study design to search deep into the biochemistry of new molecules and help take those molecules to the next stage of development,” said Gabriel.

YOU MAY BE INTERESTED IN

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login